Remarkable response to dupilumab in a 5-year-old patient with severe, recalcitrant atopic dermatitis Brian B. Johnson, MD, Lisa A. Beck, MD, S. Shahzad Mustafa, MD JAAD Case Reports Volume 5, Issue 7, Pages 605-608 (July 2019) DOI: 10.1016/j.jdcr.2019.04.012 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Therapeutic regimen from January 2018 to February 2019. JAAD Case Reports 2019 5, 605-608DOI: (10.1016/j.jdcr.2019.04.012) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 AD before dupilumab. JAAD Case Reports 2019 5, 605-608DOI: (10.1016/j.jdcr.2019.04.012) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Fig 3 AD 72 hours after loading dose. JAAD Case Reports 2019 5, 605-608DOI: (10.1016/j.jdcr.2019.04.012) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Fig 4 AD 2 weeks after loading dose. JAAD Case Reports 2019 5, 605-608DOI: (10.1016/j.jdcr.2019.04.012) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions